Alnylam Pharmaceuticals Inc. has begun enrolling patients for a phase III study of one of its most advanced experimental RNAi therapies, revusiran, a treatment for transthyretin (TTR)-mediated familial amyloidotic cardiomyopathy, a manifestation of TTR-mediated amyloidosis that afflicts about 40,000 people worldwide.